Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 398

Sort by

Sort Order Select

Journal Articles

Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma

Blood (2025) 145 (22): 2614–2629.

https://doi.org/10.1182/blood.2024024781

Published: 2025

Includes: Supplemental data

Journal Articles

Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma

Yakinthi Chrisochoidou, Andrea Scarpino, Salomon Morales, Shannon Martin, Sarah Bird, Yigen Li, Brian Walker, John Caldwell, Yann-Vaï Le Bihan, Charlotte Pawlyn

Blood (2025) 145 (22): 2630–2644.

https://doi.org/10.1182/blood.2024025861

Published: 2025

Includes: Supplemental data

Journal Articles

Classic hairy cell leukemia and concomitant smoldering myeloma

Husam Jum’ah, David Viswanatha

Blood (2025) 145 (21): 2533.

https://doi.org/10.1182/blood.2025028465

Published: 2025

Journal Articles

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Evangelos Terpos, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V. Kostopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Vasiliki Spiliopoulou, Magdalini Migkou, Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania E. Tsitsilonis, Meletios-Athanasios Dimopoulos

Blood (2025) 145 (20): 2353–2360.

https://doi.org/10.1182/blood.2024027686

Published: 2025

Journal Articles

Myelodysplastic neoplasm with biallelic TP53 inactivation in a patient with plasma cell myeloma after cytotoxic therapy

Rong He, Dong Chen

Blood (2025) 145 (19): 2230.

https://doi.org/10.1182/blood.2024028288

Published: 2025

Journal Articles

Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma

Blood (2025) 145 (17): 1876–1889.

https://doi.org/10.1182/blood.2024025694

Published: 2025

Includes: Supplemental data

Journal Articles

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial

Blood (2025) 145 (16): 1780–1787.

https://doi.org/10.1182/blood.2024027342

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS

Blood (2025) 145 (15): 1658–1669.

https://doi.org/10.1182/blood.2024025897

Published: 2025

Includes: Supplemental data

Journal Articles

Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes

Blood (2025) 145 (15): 1645–1657.

https://doi.org/10.1182/blood.2024024965

Published: 2025

Includes: Supplemental data

Journal Articles

The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

Mun Yee Koh, Tae-Hoon Chung, Nicole Xin Ning Tang, Sabrina Hui Min Toh, Jianbiao Zhou, Tze King Tan, Leilei Chen, Wee Joo Chng, Phaik Ju Teoh

Blood (2025) 145 (11): 1164–1181.

https://doi.org/10.1182/blood.2024024429

Published: 2025

Includes: Supplemental data

Journal Articles

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don Benson, Maria Chaudry, Noa Biran, Kaveri Suryanarayan, Cheryl Li, Yuyin Liu, Sabrina Collins, Xavier Parot, Jonathan L. Kaufman

Blood (2025) 145 (9): 944–955.

https://doi.org/10.1182/blood.2024026124

Published: 2025

Includes: Supplemental data

Journal Articles

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study

Blood (2025) 145 (9): 970–974.

https://doi.org/10.1182/blood.2024025624

Published: 2025

Includes: Supplemental data

Journal Articles

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Blood (2025) 145 (7): 732–747.

https://doi.org/10.1182/blood.2024025690

Published: 2025

Includes: Supplemental data

Journal Articles

Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma

Daisuke Ikeda, Shuichi Aikawa, Chiho Misono, Mitsuaki Oura, Fuminari Fujii, Hajime Sakuma, Masanori Toho, Atsushi Uehara, Rikako Tabata, Kentaro Narita, Masami Takeuchi, Tomohisa Watari, Yoshihito Otsuka, Kosei Matsue

Blood (2025) 145 (5): 526–532.

https://doi.org/10.1182/blood.2024026028

Published: 2025

Includes: Supplemental data

Journal Articles

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Blood (2025) 145 (5): 543–546.

https://doi.org/10.1182/blood.2024025868

Published: 2025

Includes: Supplemental data

Journal Articles

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Blood (2025) 145 (3): 300–310.

https://doi.org/10.1182/blood.2024025746

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy

David G. Coffey, Pinar Ataca Atilla, Erden Atilla, Ola Landgren, Andrew J. Cowan, Sylvain Simon, Margot J. Pont, Melissa L. Comstock, Geoffrey R. Hill, Stanley R. Riddell, Damian J. Green

Blood (2025) 145 (2): 220–233.

https://doi.org/10.1182/blood.2024025231

Published: 2025

Includes: Supplemental data

Journal Articles

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Blood (2025) 145 (2): 202–219.

https://doi.org/10.1182/blood.2024025987

Published: 2025

Includes: Supplemental data

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kumar, Angela Dispenzieri, Sagar Lonial, Brian G. M. Durie, Paul G. Richardson, Saad Z. Usmani, Antje Hoering, Robert Z. Orlowski

Blood (2025) 145 (1): 75–84.

https://doi.org/10.1182/blood.2024025939

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Blood (2025) 145 (1): 85–97.

https://doi.org/10.1182/blood.2024025945

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma

Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma

Classic hairy cell leukemia and concomitant smoldering myeloma

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Myelodysplastic neoplasm with biallelic TP53 inactivation in a patient with plasma cell myeloma after cytotoxic therapy

Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial

Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS

Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes

The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only